[{"NetIncomeLoss_1_Q1_USD":-39100000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":153800000.0,"Liabilities_0_Q1_USD":3015900000.0,"ContractWithCustomerAssetCreditLossExpense_1_Q1_USD":0.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0_Q1_USD":1453900000.0,"PreferredStockSharesOutstanding_0_Q1_shares":50000.0,"ProvisionForDoubtfulAccounts_1_Q1_USD":300000.0,"InventoryGross_0_Q1_USD":291100000.0,"DepreciationAndAmortization_1_Q1_USD":82700000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":206200000.0,"RepaymentsOfLongTermDebt_1_Q1_USD":1375900000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_0_Q1_USD":23500000.0,"AccruedLiabilitiesCurrent_0_Q1_USD":260900000.0,"DerivativeLiabilitiesCurrent_0_Q1_USD":39200000.0,"InventoryFinishedGoods_0_Q1_USD":174500000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-61200000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-10700000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":1414700000.0,"InventoryRawMaterialsAndSupplies_0_Q1_USD":78700000.0,"AssetsCurrent_0_Q1_USD":919800000.0,"LongTermDebt_0_Q1_USD":2411100000.0,"OtherNoncashIncomeExpense_1_Q1_USD":15900000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":131500000.0,"DebtInstrumentUnamortizedDiscount_0_Q1_USD":6300000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":16905025.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":1000000.0,"ForeignCurrencyTransactionGainLossRealized_1_Q1_USD":22900000.0,"UnrecognizedTaxBenefits_0_Q1_USD":27900000.0,"CommonStockSharesIssued_0_Q1_shares":234843052.0,"OtherAssetsNoncurrent_0_Q1_USD":99800000.0,"AmortizationOfIntangibleAssets_1_Q1_USD":33400000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-31900000.0,"IncreaseDecreaseInInventories_1_Q1_USD":41700000.0,"OtherOperatingIncomeExpenseNet_1_Q1_USD":-7400000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":28900000.0,"OtherLongTermDebt_0_Q1_USD":3600000.0,"RestructuringCosts_1_Q1_USD":1300000.0,"LettersOfCreditOutstandingAmount_0_Q1_USD":37000000.0,"GainsLossesOnExtinguishmentOfDebt_1_Q1_USD":-50300000.0,"UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_1_Q1_USD":-22000000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-50000000.0,"AccountsReceivableNetCurrent_0_Q1_USD":324100000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":3300000.0,"IncreaseDecreaseInDeferredRevenue_1_Q1_USD":-1000000.0,"NumberOfReportableSegments_1_Q1_Segment":3.0,"CommonStockValue_0_Q1_USD":0.0,"Revenues_1_Q1_USD":506800000.0,"Assets_0_Q1_USD":3392500000.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_Q1_USD":6300000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-56500000.0,"InterestPayableCurrent_0_Q1_USD":17700000.0,"DebtAndCapitalLeaseObligations_0_Q1_USD":2379700000.0,"OtherComprehensiveIncomeLossBeforeTax_1_Q1_USD":7200000.0,"ProceedsFromRepaymentsOfOtherLongTermDebt_1_Q1_USD":0.0,"DepreciationDepletionAndAmortization_1_Q1_USD":82700000.0,"ContractWithCustomerAssetNet_0_Q1_USD":49300000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":900000.0,"ForeignCurrencyTransactionGainLossUnrealized_1_Q1_USD":-22000000.0,"EffectiveIncomeTaxRateContinuingOperations_1_Q1_pure":-0.092,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":41100000.0,"StockIssuedDuringPeriodValueOther_1_Q1_USD":100000.0,"RestrictedCashEquivalentsNoncurrent_0_Q1_USD":10700000.0,"OtherAssetsCurrent_0_Q1_USD":150800000.0,"PaymentOfFinancingAndStockIssuanceCosts_1_Q1_USD":5000000.0,"OtherShortTermBorrowings_0_Q1_USD":3700000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":7200000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0_Q1_USD":63200000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":10300000.0,"CommonStockSharesOutstanding_0_Q1_shares":234843052.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q1_USD":17900000.0,"AmortizationOfFinancingCosts_1_Q1_USD":1700000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0_Q1_USD":123700000.0,"Goodwill_0_Q1_USD":576100000.0,"LongTermDebtAndCapitalLeaseObligations_0_Q1_USD":2240300000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-35800000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":3500000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q1_USD":-8800000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-9900000.0,"InventoryWorkInProcess_0_Q1_USD":37900000.0,"LiabilitiesCurrent_0_Q1_USD":564900000.0,"DeferredRevenueCurrent_0_Q1_USD":34300000.0,"AccountsPayableCurrent_0_Q1_USD":130300000.0,"InterestExpense_1_Q1_USD":43400000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1_Q1_USD":-200000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":1000000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":63400000.0,"AccruedIncomeTaxesCurrent_0_Q1_USD":3900000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q1_USD":983400000.0,"GrossProfit_1_Q1_USD":258600000.0,"AdditionalPaidInCapital_0_Q1_USD":2394300000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q1_USD":164500000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0_Q1_USD":62800000.0,"RevenueNotFromContractWithCustomer_1_Q1_USD":7100000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q1_USD":68000000.0,"PreferredStockSharesIssued_0_Q1_shares":50000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":805600000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":20300000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1956600000.0,"CapitalLeaseObligations_0_Q1_USD":900000.0,"DebtCurrent_0_Q1_USD":139400000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":1.39,"DeferredIncomeTaxAssetsNet_0_Q1_USD":7800000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0,"DeferredFinanceCostsNet_0_Q1_USD":25100000.0,"OtherComprehensiveIncomeLossTax_1_Q1_USD":0.0,"AccrualForTaxesOtherThanIncomeTaxesCurrent_0_Q1_USD":16200000.0,"CommonStockSharesAuthorized_0_Q1_shares":1000000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":499700000.0,"OperatingIncomeLoss_1_Q1_USD":57400000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q1_USD":-35800000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_1_Q1_USD":-8800000.0,"InventoryNet_0_Q1_USD":291100000.0,"ProceedsFromIssuanceInitialPublicOffering_1_Q1_USD":1426400000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":34300000.0,"ShareBasedCompensation_1_Q1_USD":3500000.0,"PreferredStockValue_0_Q1_USD":100000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":3392500000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":82300000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0_Q1_USD":62500000.0,"AmortizationOfDebtDiscountPremium_1_Q1_USD":300000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":13900000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.19,"ProfitLoss_1_Q1_USD":-39100000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":103800000.0,"StockholdersEquity_0_Q1_USD":376600000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":13400000.0,"ProceedsFromRepaymentsOfShortTermDebt_1_Q1_USD":-5400000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q1_USD":9600000.0,"AmortizationOfFinancingCostsAndDiscounts_1_Q1_USD":2400000.0,"PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_0_Q1_USD":38900000.0,"DeferredIncomeTaxExpenseBenefit_1_Q1_USD":1000000.0,"CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1_Q1_USD":248200000.0,"Ticker":"OCDX","CIK":"1828443","name":"ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC","OfficialName":"Ortho Clinical Diagnostics Holdings plc Ordinary Shares","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"4468314033.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20210518"}]